Non-oncology diseases with accelerated approval therapies carried a heavier societal toll
Diseases treated through the FDA’s accelerated approval pathway were associated with substantially higher economic burden than comparison diseases without such therapies. In a cross-disease analysis of non-oncology indications approved from January 2015 through February 2025, the average annual incremental societal cost reached $91,857 for accelerated-approval diseases versus $65,468 for non-AA diseases, a difference that was statistically significant. The pattern was not limited to direct spending. Productivity loss and caregiver burden also ran higher in the accelerated-approval group, pointing to disorders that do more than consume healthcare resources — they erode function, work participation, and family capacity in parallel.
The signal is clinically coherent. Diseases severe enough to warrant expedited regulatory review often affect patients earlier in life, persist for years, and require sustained caregiving. In practical terms, the economic profile mirrors the biology: conditions with shorter life expectancy, lower quality of life, and greater rarity tend to generate disproportionate downstream costs because they combine chronic disability with limited therapeutic alternatives.
The economic gap widened beyond direct medical costs
The analysis identified 32 non-oncology accelerated-approval treatments spanning 16 unique diseases. For the comparison group, 100 non-oncology diseases with the most recent FDA-approved non-AA therapies served as the reference set. Annual burden estimates were drawn from peer-reviewed literature, with costs inflated to 2025 US dollars and studies using a societal perspective prioritized when available. Comparative testing used the Mann-Whitney U Test, an approach suited to skewed burden data that rarely follow a normal distribution.
The most striking difference involved overall societal cost. The accelerated-approval diseases carried 1.4 times the annual incremental societal cost of the comparison diseases. Productivity loss was 1.8 times higher, rising to $17,635 versus $9,620, although the p value of 0.092 left that estimate short of conventional statistical significance. Caregiver burden followed the same direction and was even larger in magnitude, at 2.4 times the comparator burden, or $20,268 versus $8,294; here too, the p value of 0.055 suggested a strong trend without crossing the usual significance threshold.
One sentence captures the policy problem: these are not mild disorders waiting for a marginal benefit. They are expensive, disabling conditions with spillover costs that extend well beyond clinic walls.
Severity markers tracked with the regulatory profile
The disease features linked to accelerated-approval therapies were also more severe. Average life expectancy in the AA diseases was 59.3 years, compared with 65.1 years in the non-AA group. Average quality of life was lower as well, at 0.64 versus 0.69. A larger share of the accelerated-approval conditions were rare diseases, 68.8% versus 53.1% in the comparator set.
Those characteristics matter because they help explain why accelerated approval is used in the first place. The pathway is reserved for serious or life-threatening conditions in which earlier access to a drug may be justified by surrogate evidence rather than waiting for a complete traditional evidence package. In non-oncology medicine, that framework often intersects with diseases where irreversible organ damage, progressive disability, or early mortality make therapeutic delay particularly costly. Lower baseline quality of life also means even modest gains can translate into meaningful patient benefit, while delays in coverage can deepen cumulative harm.
Coverage policy meets unmet need
For payers, the findings sharpen a difficult question: how should coverage decisions account for diseases that are both expensive and clinically severe, yet supported by an expedited approval pathway that may rely on incomplete evidence at launch? The analysis argues for considering not only the evidentiary status of the drug but also the burden of the underlying disease. A coverage policy that treats all accelerated-approval indications as interchangeable risks missing the difference between a low-burden disorder and one that drives repeated hospital use, lost employment, and intensive caregiving.
At the same time, the data do not resolve how quickly coverage should follow approval or which evidentiary thresholds should be required before reimbursement is granted. The study also does not measure post-coverage outcomes, actual payer behavior, or whether access restrictions differ across therapeutic areas. Those gaps leave an important practical question in place: whether the burden profile of a disease should accelerate coverage just as regulatory urgency accelerated approval.
What the burden estimates do and do not prove
The findings describe association, not causation. The higher burden observed in diseases with accelerated-approval therapies may reflect the severity of the underlying condition, the scarcity of alternative treatments, or both. It may also reflect the way rare and progressive diseases concentrate costs in outpatient care, hospital utilization, lost productivity, and unpaid caregiving. None of that establishes that accelerated approval itself causes higher burden; instead, it shows that the pathway is disproportionately attached to diseases already imposing severe costs on patients and society.
Still, the pattern is difficult to dismiss. The combination of shorter life expectancy, worse quality of life, greater rarity, and larger societal burden suggests that accelerated-approval indications cluster in areas of clear unmet need. For clinicians, that means patients are often living with disorders where the consequences of delayed access are substantial. For payers, it means denying or slowing coverage may carry a larger downstream human and economic price than in lower-burden disease states.
The central policy tension remains in place: accelerated approval can speed access, but access without timely coverage may blunt the very benefit the pathway is designed to deliver. In non-oncology medicine, where the burden profile is especially steep, that gap can be felt in wages lost, caregiving hours accumulated, and progressive disability that continues while coverage decisions lag.